Home
PTGX
PTGX News

Latest Protagonist Therapeutics Inc. (PTGX) News on April 2, 2025

Argus Research

7 days ago

PTGX: Lowering target price to $54.00

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Zacks

8 days ago

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey

15 days ago

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

FastCompany

15 days ago

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

ACCESS Newswire

15 days ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Insider Monkey

17 days ago

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Zacks

20 days ago

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

Zacks

21 days ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Zacks

22 days ago

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

MT Newswires

22 days ago

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

GuruFocus.com

22 days ago

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Clinical Trials Arena

22 days ago

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Insider Monkey

22 days ago

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Investor's Business Daily

22 days ago

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

MT Newswires

22 days ago

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires

22 days ago

Top Midday Gainers

MT Newswires

23 days ago

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating

MT Newswires

23 days ago

Protagonist, Johnson & Johnson Say Phase 2b Icotrokinra Study Meets Primary Endpoint in Ulcerative Colitis

ACCESS Newswire

23 days ago

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire

25 days ago

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Argus Research

a month ago

PTGX: Rating decreased to a SELL

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Simply Wall St.

a month ago

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga

a month ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide

Clinical Trials Arena

a month ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

MT Newswires

a month ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire

a month ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

BioPharma Dive

a month ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Argus Research

a month ago

PTGX: Lowering target price to $37.00

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Simply Wall St.

a month ago

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks

a month ago

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Associated Press Finance

a month ago

Protagonist Therapeutics: Q4 Earnings Snapshot

MT Newswires

a month ago

Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise

ACCESS Newswire

a month ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Argus Research

a month ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Insider Monkey

2 months ago

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

Argus Research

2 months ago

PTGX: Lowering target price to $39.00

Biotech walks a 'tightrope' amid unclear funding, regulations

Yahoo Finance Video

2 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ACCESS Newswire

2 months ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Argus Research

2 months ago

PTGX: What does Argus have to say about PTGX?

Argus Research

2 months ago

PTGX: Raising target price to $40.00

Argus Research

3 months ago

PTGX: Lowering target price to $39.00

ACCESSWIRE

3 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Argus Research

3 months ago

PTGX: What does Argus have to say about PTGX?

ACCESSWIRE

3 months ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Argus Research

3 months ago

PTGX: Lowering target price to $43.00

Argus Research

4 months ago

PTGX: Raising target price to $44.00

ACCESSWIRE

4 months ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

MT Newswires

4 months ago

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

TipRanks

4 months ago

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

Argus Research

4 months ago

PTGX: Lowering target price to $43.00

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

4 months ago

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 11/29/2024

MT Newswires

4 months ago

Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing

MT Newswires

4 months ago

Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing

MT Newswires

4 months ago

Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing

Argus Research

4 months ago

PTGX: Raising target price to $47.00

ACCESSWIRE

4 months ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

ACCESSWIRE

4 months ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

4 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

4 months ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Zacks

5 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Argus Research

5 months ago

PTGX: Lowering target price to $45.00

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Protagonist Therapeutics: Q3 Earnings Snapshot

ACCESSWIRE

5 months ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Argus Research

5 months ago

PTGX: Lowering target price to $48.00

ACCESSWIRE

5 months ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

MT Newswires

5 months ago

Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target

ACCESSWIRE

5 months ago

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

Insider Monkey

5 months ago

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

GuruFocus.com

6 months ago

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

Argus Research

6 months ago

PTGX: Lowering target price to $46.00

MT Newswires

6 months ago

TD Cowen Initiates Protagonist Therapeutics at Buy

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Benzinga

7 months ago

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years

Simply Wall St.

7 months ago

Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years

ACCESSWIRE

7 months ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Argus Research

7 months ago

PTGX: What does Argus have to say about PTGX?

Argus Research

7 months ago

PTGX: Raising target price to $44.00

MT Newswires

8 months ago

Protagonist Therapeutics Shares Fall After Q2 Revenue Miss

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates

Zacks

8 months ago

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

8 months ago

Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ACCESSWIRE

8 months ago

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

ACCESSWIRE

8 months ago

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

ACCESSWIRE

8 months ago

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

ACCESSWIRE

8 months ago

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

MT Newswires

8 months ago

JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating

MT Newswires

8 months ago

BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating

Argus Research

8 months ago

PTGX: What does Argus have to say about PTGX?

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

ACCESSWIRE

8 months ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

8 months ago

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Argus Research

9 months ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Investor's Business Daily

9 months ago

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Associated Press

9 months ago

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

MT Newswires

9 months ago

Protagonist Therapeutics to Join S&P SmallCap 600

Protagonist Therapeutics Set to Join S&P SmallCap 600

PR Newswire

9 months ago

Protagonist Therapeutics Set to Join S&P SmallCap 600

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

Insider Monkey

9 months ago

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Simply Wall St.

10 months ago

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

ACCESSWIRE

10 months ago

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

MT Newswires

10 months ago

Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing

MT Newswires

10 months ago

Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing

Share on Social Networks: